U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22O8
Molecular Weight 414.4053
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PODOFILOX

SMILES

COC1=CC(=CC(OC)=C1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)C4=CC5=C(OCO5)C=C24

InChI

InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603 http://products.sanofi.ca/en/condyline.pdf

Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: CHEMBL2095182
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CONDYLOX

Approved Use

Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (49.4%)
Pain (54.3%)
Itching (59.3%)
Bleeding (29.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (79.2%)
Pain (79.2%)
Itching (83.3%)
Bleeding (45.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (52.3%)
Pain (55.8%)
Itching (60.5%)
Bleeding (32.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (83.2%)
Pain (49.6%)
Itching (52.9%)
Bleeding (28.6%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (71.4%)
Pain (71.4%)
Itching (57.1%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (81.9%)
Pain (50.4%)
Itching (52.8%)
Bleeding (26.8%)
Sources:
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (mild, 32.2%)
Pain (mild, 23.7%)
Itching (mild, 32.2%)
Bleeding (mild, 19.2%)
Inflammation (moderate, 30.4%)
Pain (moderate, 20.4%)
Itching (moderate, 16%)
Bleeding (moderate, 3%)
Inflammation (severe, 9.3%)
Pain (severe, 11.5%)
Itching (severe, 7.8%)
Bleeding (severe, 0.7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bleeding 29.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Inflammation 49.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Pain 54.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Itching 59.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Bleeding 45.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Inflammation 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Pain 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Itching 83.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Bleeding 32.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Inflammation 52.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Pain 55.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Itching 60.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Bleeding 28.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Pain 49.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Itching 52.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Inflammation 83.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Itching 57.1%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Inflammation 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Pain 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Bleeding 26.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Pain 50.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Itching 52.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Inflammation 81.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M
Sources:
Bleeding mild, 19.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Pain mild, 23.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Inflammation mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Itching mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Itching moderate, 16%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Pain moderate, 20.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Bleeding moderate, 3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Inflammation moderate, 30.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Bleeding severe, 0.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Pain severe, 11.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Itching severe, 7.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Inflammation severe, 9.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
unhealthy, adult
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Imiquimod for the treatment of genital warts: a quantitative systematic review.
2001
Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
2001 Dec
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species.
2001 Dec
Podophyllin office therapy against condyloma should be abandoned.
2001 Dec
The treatment of anogenital warts at home.
2001 Feb 8-14
GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart.
2001 Jan 12
A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.
2001 Jun
Management of anogenital warts (condylomata acuminata).
2001 Nov-Dec
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
2001 Oct
Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream.
2001 Sep-Oct
Facial molluscum: treatment with cryotherapy and podophyllotoxin.
2002 Apr
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
2002 Dec 15
Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
2002 Feb
Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells.
2002 Jun 14
Deoxypodophyllotoxin; the cytotoxic and antiangiogenic component from Pulsatilla koreana.
2002 Mar
Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
2002 Mar
Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex.
2002 Mar 14
External genital warts: diagnosis, treatment, and prevention.
2002 Oct 15
Cytogenetic analysis of giant oocytes and zygotes to assess their relevance for the development of digynic triploidy.
2002 Sep
Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription.
2003 Apr 11
Naphthalene analogues of lignans.
2003 Feb 7
[Bacteremia due to Capnocytophaga spp.: two cases].
2003 Mar
Patents

Sample Use Guides

Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Name Type Language
Podophyllotoxin
MART.   MI   WHO-DD  
Preferred Name English
PODOFILOX
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
PODOPHYLLOTOXIN [EP MONOGRAPH]
Common Name English
NSC-24818
Code English
PODOFILOX [VANDF]
Common Name English
PODOFILOX [ORANGE BOOK]
Common Name English
Podophyllotoxin [WHO-DD]
Common Name English
PODOPHYLLOTOXIN [MI]
Common Name English
PODOPHYLLOTOXIN [MART.]
Common Name English
CONDYLOX
Brand Name English
PODOFILOX [HSDB]
Common Name English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.ALPHA.))-
Common Name English
(5R,5AR,8AR,9R)-5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
Common Name English
PODOFILOX [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008732
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
NCI_THESAURUS C67421
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
WHO-ATC D06BB04
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
WHO-VATC QD06BB04
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
Code System Code Type Description
PUBCHEM
10607
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
HSDB
7238
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
EVMPD
SUB14925MIG
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
RXCUI
8463
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY RxNorm
MERCK INDEX
m8933
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL61
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
NSC
24818
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
CAS
518-28-5
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
FDA UNII
L36H50F353
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
NCI_THESAURUS
C29368
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
WIKIPEDIA
PODOPHYLLOTOXIN
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DRUG CENTRAL
3481
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
SMS_ID
100000091097
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
CHEBI
50305
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
MESH
D011034
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
USAN
AA-10
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-250-4
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
EPA CompTox
DTXSID3045645
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DRUG BANK
DB01179
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY
DAILYMED
L36H50F353
Created by admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
PRIMARY